Educational review: Role of the surgeon in hereditary breast cancer

Annals of Surgical Oncology

Volumn 8, Issue 4, 2001, Pages 368-378

  Newman, L A ^a   Kuerer, H M ^a   Hunt, K K ^a   Vlastos, G ^a   Ames, F C ^a   Ross, M I ^a   Singletary, S E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Hereditary breast cancer; Prophylaxis; Surgery

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RISK; CONSERVATIVE TREATMENT; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC DISORDER; GENETIC PREDISPOSITION; HUMAN; ONCOGENE; OVARY CANCER; PROGNOSIS; UNITED STATES;

ADULT; AGED; BRCA2 PROTEIN; BREAST NEOPLASMS; CHEMOPREVENTION; FEMALE; GENES, BRCA1; GENETIC COUNSELING; GENETIC SCREENING; HUMANS; LIFE STYLE; MASTECTOMY; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; OVARIECTOMY; PEDIGREE; PROGNOSIS; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 0035025509     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/aso.2001.8.4.368     Document Type: Article

References (79)

1. Breast cancer genetics: Toward molecular characterization of individuals at increased risk for breast cancer: Part I
2. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
3. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13
4. Breast and ovarian cancer incidence in BRCA 1-mutation carriers: Breast Cancer Linkage Consortium
5. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
6. Population-based study of risk of breast cancer in carriers of BRCA2 mutation
7. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer
8. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women
9. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer
10. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk
11. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2
12. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%
13. Ethnic differences in cancer risk resulting from genetic variation
14. Recurrent germ-line mutations in extended African American families with early-onset breast cancer
15. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
16. Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
17. Autosomal dominant inheritance of early-onset breast cancer: Implications for risk prediction
18. BRCA1 sequence analysis in women at high risk for susceptibility mutations: Risk assessment factor analysis and implications for genetic testing
19. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer
20. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility
21. The concise handbook of family cancer syndromes: Mayo Clinic Familial Cancer Program
22. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2
23. Analysis of the risk reduction of prophylactic partial mastectomy in Sprague-Dawley rats with 7,12-dimethylbenzanthracene-induced breast cancer
24. Effectiveness of prophylactic mastectomy in the prevention of breast tumors in C3H mice
25. Collective review: Prophylactic mastectomy
26. Subcutaneous mastectomy data: A final statistical analysis
27. Conservative management in full-thickness nipple-areolar necrosis after subcutaneous mastectomy
28. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
29. Bilateral prophylactic mastectomy in BRCA1/2 mutation carriers
30. The hazard of incomplete simple mastectomy
31. Cancer of the breast after prophylactic subcutaneous mastectomy
32. Failure of subcutaneous mastectomy to prevent the development of breast cancer
33. Metastatic breast cancer 42 years after bilateral subcutaneous mastectomies
34. Primary breast cancer after prophylactic mastectomy
35. Breast carcinoma in residual breast tissue after prophylactic bilateral subcutaneous mastectomy
36. Decision analysis: Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations
37. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients
38. A prospective study of psychiatric and psychosocial sequelae of bilateral subcutaneous mastectomy
39. Sexual identity and prophylactic mastectomy
40. Predictors of and satisfaction with prophylactic mastectomy
41. Acceptability of prophylactic mastectomy in cancer-prone women
42. Issues of regret in women with contralateral prophylactic mastectomies
43. Women's regrets after bilateral prophylactic mastectomy
44. Insurance adjudication favoring prophylactic surgery in hereditary breast-ovarian cancer syndrome
45. Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery
46. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers
47. Tumour biological features of BRCA1-induced breast and ovarian cancer
48. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen chemoprevention trial
49. Breast cancer risk associated with gynecologic surgery and indications for such surgery
50. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
51. Risk modifiers in carriers of BRCA1 mutations
52. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies
53. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?
54. Oral contraceptives and the risk of hereditary ovarian cancer
55. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes
56. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: A decision analysis
57. Genetic counseling for BRCA1/BRCA2 testing
58. Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations: Austrian Hereditary Breast and Ovarian Cancer Group
59. What you don't know can hurt you: Adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing
60. A descriptive study of BRCA1 testing and reactions to disclosure of test results
61. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases
62. BRCA-associated breast cancer: Absence of a characteristic immunophenotype
63. Survival and tumour characteristics of breast cancer patients with germline mutations of BRCA1
64. Mutations at BRCA1: The medullary breast carcinoma revisited
65. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: A population-based study
66. Survival in breast cancer associated with BRCA2 germline mutation is not different from the outcome in sporadic breast cancer
67. BRCA-associated cancer in young women
68. Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden
69. No deleterious effect of radiotherapy in women who are heterozygote for a BRCA1 or BRCA2 mutation following breast-conserving therapy
70. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations
71. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: Implications for breast-conserving management in patients with BRCA1/BRCA2 mutations
72. Rationale for elective contralateral mastectomy with immediate bilateral reconstruction
73. Bilateral breast carcinoma versus unilateral disease: Review of 498 patients
74. Survival from contralateral breast cancer
75. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations
76. Causes of breast cancer malpractice litigation: A 20-year civil court review
77. Genetic susceptibility for specific cancers: Medical liability for the clinician
78. SSO develops position statement on prophylactic mastectomies
79. The woman at increased risk for breast cancer: Evaluation and management strategies